CoTherix Will Position Ventavis As Complement To Oral Pulmonary Arterial Hypertension Therapies
This article was originally published in The Pink Sheet Daily
Executive Summary
Iloprost will launch in the second quarter 2005. CoTherix views the inhaled therapy as filling the “substantial therapeutic gap” between oral agents like Tracleer and injectable drugs such as Remodulin.
You may also be interested in...
Ventavis To Cost $65,000 - $100,000 Per Year, CoTherix Says
The PAH therapy is competitively priced against United Therapeutics' Remodulin and Actelion's Tracleer, CoTherix says. With its sales force still in training, Ventavis has launched ahead of schedule.
Ventavis To Cost $65,000 - $100,000 Per Year, CoTherix Says
The PAH therapy is competitively priced against United Therapeutics' Remodulin and Actelion's Tracleer, CoTherix says. With its sales force still in training, Ventavis has launched ahead of schedule.
Ventavis Price To Be Based On Input From Payors And Physicians, CoTherix Says
CoTherix will base its price for the inhaled pulmonary arterial hypertension therapy Ventavis on the outcome of ongoing discussions with payors and physicians